PE20121702A1 - Proteinas de enlace cd127 - Google Patents
Proteinas de enlace cd127Info
- Publication number
- PE20121702A1 PE20121702A1 PE2012001071A PE2012001071A PE20121702A1 PE 20121702 A1 PE20121702 A1 PE 20121702A1 PE 2012001071 A PE2012001071 A PE 2012001071A PE 2012001071 A PE2012001071 A PE 2012001071A PE 20121702 A1 PE20121702 A1 PE 20121702A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdrh2
- cdrh3
- lysine
- residue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
REFERIDA A UN ANTICUERPO HUMANIZADO QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE UNA, DOS O TRES DE LAS SIGUIENTES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD: i) CDRH1 DE SEQ ID Nº:2, ii) CDRH2 DE SEQ ID Nº:3, iii) CDRH3 DE SEQ ID Nº:4 O UNA CDRH3 DE SEQ ID Nº: 132 - 137, DONDE EL ANTICUERPO COMPRENDE UN RESIDUO DE LISINA EN LA POSICION 66, UN RESIDUO DE LISINA EN LA POSICION 69, O UNA VALINA EN LA POSICION 71 DE LA REGION VARIABLE DE CADENA PESADA. TAMBIEN ESTA REFERIDA A UNA PROTEINA DE ENLACE, UN VECTOR, UNA CELULA HUESPED Y UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS ACTUAN SOBRE EL RECEPTOR DE IL-7 HUMANO (CD127) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES TALES COMO LA ESCLEROSIS MULTIPLE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29901010P | 2010-01-28 | 2010-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121702A1 true PE20121702A1 (es) | 2012-12-14 |
Family
ID=44320081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000247A PE20170687A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace a cd127 |
| PE2012001071A PE20121702A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace cd127 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000247A PE20170687A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace a cd127 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8940303B2 (es) |
| EP (1) | EP2528947A4 (es) |
| JP (1) | JP5850860B2 (es) |
| KR (1) | KR20130028055A (es) |
| CN (1) | CN102812046B (es) |
| AR (1) | AR080027A1 (es) |
| AU (1) | AU2011209713B2 (es) |
| BR (1) | BR112012018914A2 (es) |
| CA (1) | CA2787070A1 (es) |
| CL (1) | CL2012002081A1 (es) |
| CO (1) | CO6592067A2 (es) |
| CR (1) | CR20120404A (es) |
| EA (1) | EA023700B1 (es) |
| IL (1) | IL220899A (es) |
| MA (1) | MA34004B1 (es) |
| MX (1) | MX339083B (es) |
| MY (1) | MY160590A (es) |
| NZ (1) | NZ601271A (es) |
| PE (2) | PE20170687A1 (es) |
| PH (1) | PH12012501549A1 (es) |
| SG (1) | SG182590A1 (es) |
| TW (1) | TWI489996B (es) |
| UA (1) | UA104663C2 (es) |
| UY (1) | UY33202A (es) |
| WO (1) | WO2011094259A2 (es) |
| ZA (1) | ZA201205624B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2858350A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| KR20170065662A (ko) | 2014-10-18 | 2017-06-13 | 화이자 인코포레이티드 | 항-il-7r 항체 조성물 |
| KR102789821B1 (ko) | 2015-03-31 | 2025-04-02 | 소리소 파마슈티컬스 인크. | 프로테아제-절단가능 링커를 갖는 펩티드 구조물 |
| JP2018511346A (ja) | 2015-03-31 | 2018-04-26 | ブイエイチスクエアード リミテッド | ポリペプチド |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| JP7183042B2 (ja) * | 2016-01-07 | 2022-12-05 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 眼の免疫炎症性疾患のための治療法 |
| KR102819051B1 (ko) | 2016-02-29 | 2025-06-12 | 오제 이뮈노테라프틱스 | Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도 |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| US11098128B2 (en) * | 2016-12-09 | 2021-08-24 | Ose Immunotherapeutics | Antibodies and polypeptides directed against CD127 |
| WO2019136180A2 (en) * | 2018-01-04 | 2019-07-11 | Avidity Biosciences Llc | Heteroduplex nucleic acid molecules and uses thereof |
| EP3914622A1 (en) * | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| EP3986570A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Compositions |
| EP3986571A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN114514243B (zh) | 2019-06-21 | 2025-01-24 | 索瑞索制药公司 | 多肽 |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| ES3023172T3 (en) | 2022-05-30 | 2025-05-30 | Ose Immunotherapeutics | Biomarkers of il7r modulator activity |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4646439A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| CN121002069A (zh) | 2023-01-06 | 2025-11-21 | 泰温治疗私人有限公司 | 抗原结合分子 |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| FI915911A0 (fi) * | 1989-06-15 | 1991-12-16 | Immunex Corp | Interleukin-7-receptorer. |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| ATE346867T1 (de) * | 1994-12-23 | 2006-12-15 | Smithkline Beecham Corp | Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| WO1997042329A1 (en) | 1996-05-04 | 1997-11-13 | Zeneca Limited | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
| CA2280195A1 (en) | 1997-02-07 | 1998-08-13 | Merck & Co., Inc. | Synthetic hiv gag genes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2002541482A (ja) * | 1999-04-13 | 2002-12-03 | ヴィレックス アクチェンゲゼルシャフト | 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用 |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| EP1641818B1 (en) | 2003-07-04 | 2008-12-03 | Affibody AB | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2005056764A2 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
| AU2005269759A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
| RU2493167C2 (ru) * | 2006-12-18 | 2013-09-20 | Дженентек, Инк. | АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| JP2011509687A (ja) * | 2008-01-22 | 2011-03-31 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｒｏｎ抗体およびその使用 |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
-
2011
- 2011-01-26 KR KR1020127022553A patent/KR20130028055A/ko not_active Abandoned
- 2011-01-26 US US13/013,993 patent/US8940303B2/en not_active Expired - Fee Related
- 2011-01-26 MX MX2012008765A patent/MX339083B/es active IP Right Grant
- 2011-01-26 WO PCT/US2011/022507 patent/WO2011094259A2/en not_active Ceased
- 2011-01-26 PE PE2017000247A patent/PE20170687A1/es not_active Application Discontinuation
- 2011-01-26 TW TW100102962A patent/TWI489996B/zh not_active IP Right Cessation
- 2011-01-26 NZ NZ601271A patent/NZ601271A/en not_active IP Right Cessation
- 2011-01-26 EP EP11737543.6A patent/EP2528947A4/en not_active Withdrawn
- 2011-01-26 CA CA2787070A patent/CA2787070A1/en not_active Abandoned
- 2011-01-26 MA MA35147A patent/MA34004B1/fr unknown
- 2011-01-26 EA EA201290589A patent/EA023700B1/ru not_active IP Right Cessation
- 2011-01-26 BR BR112012018914A patent/BR112012018914A2/pt not_active IP Right Cessation
- 2011-01-26 PH PH1/2012/501549A patent/PH12012501549A1/en unknown
- 2011-01-26 MY MYPI2012003394A patent/MY160590A/en unknown
- 2011-01-26 UA UAA201209254A patent/UA104663C2/ru unknown
- 2011-01-26 US US13/574,847 patent/US9150653B2/en not_active Expired - Fee Related
- 2011-01-26 JP JP2012551247A patent/JP5850860B2/ja not_active Expired - Fee Related
- 2011-01-26 AU AU2011209713A patent/AU2011209713B2/en not_active Ceased
- 2011-01-26 PE PE2012001071A patent/PE20121702A1/es not_active Application Discontinuation
- 2011-01-26 SG SG2012053138A patent/SG182590A1/en unknown
- 2011-01-26 CN CN201180015856.0A patent/CN102812046B/zh not_active Expired - Fee Related
- 2011-01-26 AR ARP110100251A patent/AR080027A1/es unknown
- 2011-01-26 UY UY0001033202A patent/UY33202A/es not_active Application Discontinuation
-
2012
- 2012-07-12 IL IL220899A patent/IL220899A/en not_active IP Right Cessation
- 2012-07-24 CO CO12124175A patent/CO6592067A2/es active IP Right Grant
- 2012-07-25 ZA ZA2012/05624A patent/ZA201205624B/en unknown
- 2012-07-26 CL CL2012002081A patent/CL2012002081A1/es unknown
- 2012-07-31 CR CR20120404A patent/CR20120404A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| EA201390993A1 (ru) | Антитела к cd38 | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JOP20190097A1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| EP4349868A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
| EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| PE20141548A1 (es) | Anticuerpo anti-alfabeta tcr | |
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
| PE20110413A1 (es) | Anticuerpos neutralizantes de la glicoproteina b de citomegalovirus humano | |
| UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| EA201000424A1 (ru) | Антитела к il-23 | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| PE20171512A1 (es) | Anticuerpos anti-fap | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| EA201492149A8 (ru) | St2-антигенсвязывающие белки | |
| MX2013011706A (es) | Proteinas novedosas de enlace a antigeno. | |
| MX382826B (es) | Anticuerpos dkk1 y metodos de uso. | |
| MX337873B (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. | |
| UA113728C2 (xx) | Фармацевтична композиція, яка містить антитіло до pcsk9 людини | |
| MX2010004482A (es) | Anticuerpos anti-proteina g vsr. | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |